Multiple therapies blocking TGF-β signaling have been investigated in preclinical and clinical trials over the past few decades; nevertheless, the outcomes of clinical trials are disappointing due to the double-faced systemic effects of TGF-β and the complexity of the tumor microenvironment. The gene discussed is TGFB1; the disease is neoplasm.